Merck (MRK) insider Chirfi Guindo files to sell 20,000 shares under Rule 144

Rhea-AI Filing Summary

Merck & Co. insider plans stock sale under Rule 144. A person named Chirfi Guindo filed to sell 20,000 shares of Merck common stock through Morgan Stanley Smith Barney LLC on or around 02/09/2026 on the NYSE, with an aggregate market value of $2,368,202.00.

The 20,000 shares were acquired on 08/03/2023 via restricted stock vesting under a registered plan. Over the past three months, the same seller disposed of another 20,000 Merck shares on 02/05/2026 for gross proceeds of $2,437,676.00. Merck had 2,482,022,536 shares outstanding. The seller represents awareness of no undisclosed material adverse information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	2368202.00	2482022536	02/09/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/03/2023	Restricted stock vesting under a registered plan	Issuer			20000	08/03/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHIRFI GUINDO 126 East Lincoln Avenue Rahway NJ 07065	Common	02/05/2026	20000	2437676.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Merck (MRK) Form 144 filing by Chirfi Guindo disclose?

The filing discloses an intent to sell 20,000 Merck common shares under Rule 144. The planned sale is through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of about $2.37 million, based on the figures in the notice.

How many Merck (MRK) shares is the insider planning to sell and when?

The insider plans to sell 20,000 Merck common shares. The notice lists an approximate sale date of 02/09/2026, with the transaction expected to occur on the NYSE through Morgan Stanley Smith Barney LLC’s Executive Financial Services group.

What was the source of the 20,000 Merck (MRK) shares to be sold?

The 20,000 Merck shares came from restricted stock vesting under a registered company plan. They were acquired on 08/03/2023 directly from the issuer, with the filing indicating the nature of the acquisition as stock vesting rather than a cash purchase.

What prior Merck (MRK) stock sales has Chirfi Guindo made recently?

Over the past three months, the filer sold 20,000 Merck common shares on 02/05/2026. The filing reports $2,437,676.00 in gross proceeds from that transaction, showing one prior significant sale in the recent quarter in addition to the newly planned sale.

How large is the planned Merck (MRK) sale compared to shares outstanding?

Merck had 2,482,022,536 common shares outstanding. The planned sale of 20,000 shares is a very small fraction of this total, indicating the transaction is minimal relative to the company’s overall equity base as reported in the notice.

Does the Merck (MRK) Rule 144 filer claim to have inside adverse information?

The filer represents that they do not know any material adverse information about Merck’s current or prospective operations that has not been publicly disclosed, as required in the notice text and consistent with Rule 144 representations when submitting such a filing.